13F filer · CIK 1940272
ADAR1 Capital Management, LLC
AUSTIN, TX · filing since Q4 2023 · last filing Aug 14, 2026
Reported value
$2.2B
+$487.5M vs prior
Positions
277
New / sold out
47 / 80
Added / reduced
100 / 64
Turnover
21.3%
buys $627.5M · sells $414.1M
Top-10 weight
40.8%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | ABIVAX SA | +410,684 | +29.5% | +$54.7M |
| Added | AGIOS PHARMACEUTICALS INC | +1,147,381 | +815.6% | +$42.6M |
| Added | SPYSTATE STR SPDR S&P 500 ETF T | +53,147 | +70.0% | +$39.7M |
| Added | ZAI LAB LTD | +1,943,667 | +136.4% | +$36.9M |
| New | EDITAS MEDICINE INC | +8,889,000 | – | +$28.8M |
| Added | PRAXIS PRECISION MEDICINES I | +72,753 | +4850.2% | +$24.4M |
| Added | INSMED INC | +193,128 | +545.7% | +$20.6M |
| Added | ENANTA PHARMACEUTICALS INC | +1,293,153 | +2518.0% | +$18.9M |
| New | SPYSTATE STR SPDR S&P 500 ETF TPUT | +25,000 | – | +$18.7M |
| Added | RALLYBIO CORP | +905,817 | +4411.1% | +$14.5M |
137 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | TERNS PHARMACEUTICALS INC | -914,699 | -100.0% | $-48.2M |
| Sold out | BEAM THERAPEUTICS INC | -1,446,375 | -100.0% | $-34.5M |
| Reduced | DENALI THERAPEUTICS INC | -842,375 | -45.0% | $-21.7M |
| Sold out | SCHOLAR ROCK HLDG CORP | -407,273 | -100.0% | $-20.0M |
| Reduced | CYTOKINETICS INC | -174,649 | -27.6% | $-14.9M |
| Reduced | IMMUNOVANT INC | -348,294 | -13.0% | $-13.4M |
| Reduced | MAPLIGHT THERAPEUTICS INC | -348,412 | -92.9% | $-12.5M |
| Reduced | SANOFI SA | -259,839 | -82.0% | $-11.1M |
| Sold out | TERNS PHARMACEUTICALS INCCALL | -200,000 | -100.0% | $-10.5M |
| Reduced | REPLIMUNE GROUP INC | -927,203 | -58.6% | $-10.3M |
134 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ABIVAX SASPONSORED ADS | 1,804,703 | $240.5M | 11.01% |
| 2 | PROTAGONIST THERAPEUTICS INCCOM | 960,863 | $117.8M | 5.39% |
| 3 | ROIVANT SCIENCES LTDSHS | 3,157,008 | $111.7M | 5.11% |
| 4 | SPYSTATE STR SPDR S&P 500 ETF T | 129,087 | $96.4M | 4.41% |
| 5 | IMMUNOVANT INCCOM | 2,330,716 | $89.8M | 4.11% |
| 6 | ZAI LAB LTDADR | 3,369,034 | $64.0M | 2.93% |
| 7 | AGIOS PHARMACEUTICALS INCCOM | 1,288,053 | $47.8M | 2.19% |
| 8 | CRINETICS PHARMACEUTICALS INCOM | 1,222,080 | $45.7M | 2.09% |
| 9 | EA SERIES TRUSTALPHA ARCH 1-3 | 337,125 | $39.5M | 1.81% |
| 10 | CYTOKINETICS INCCOM NEW | 457,907 | $39.0M | 1.79% |
267 more rows. Subscribe for $29/month to see every row, download the data and use the API.